[go: up one dir, main page]

BRPI0516572A - métodos e composições para melhorar a produção de proteìnas recombinantes - Google Patents

métodos e composições para melhorar a produção de proteìnas recombinantes

Info

Publication number
BRPI0516572A
BRPI0516572A BRPI0516572-5A BRPI0516572A BRPI0516572A BR PI0516572 A BRPI0516572 A BR PI0516572A BR PI0516572 A BRPI0516572 A BR PI0516572A BR PI0516572 A BRPI0516572 A BR PI0516572A
Authority
BR
Brazil
Prior art keywords
recombinant proteins
methods
compositions
improving
production
Prior art date
Application number
BRPI0516572-5A
Other languages
English (en)
Inventor
Martin S Sinacore
Mark Leonard
Haley A Laken
Jason Rouse
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0516572A publication Critical patent/BRPI0516572A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA MELHORAR A PRODUçãO DE PROTEìNAS RECOMBINANTES. A invenção refere-se a moléculas de ácidos nucléicos, modificadas para intensificar a expressão de proteínas recombinantes, como por exemplo, anticorpos, e/ou reduzir ou eliminar subprodutos mal separados e/ou "read-through" de íntrons. A invenção fornece também métodos para produzir proteínas isentas de subprodutos mal separados e/ou "read-through" de íntrons pelo uso de tais vetores em células hospedeiras, sob condições de cultura de células apropriadas para a expressão de proteínas recombinantes.
BRPI0516572-5A 2004-10-05 2005-10-05 métodos e composições para melhorar a produção de proteìnas recombinantes BRPI0516572A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61647404P 2004-10-05 2004-10-05
PCT/US2005/036247 WO2006042158A2 (en) 2004-10-05 2005-10-05 Methods and compositions for improving recombinant protein production

Publications (1)

Publication Number Publication Date
BRPI0516572A true BRPI0516572A (pt) 2008-09-16

Family

ID=35710394

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0516572-5A BRPI0516572A (pt) 2004-10-05 2005-10-05 métodos e composições para melhorar a produção de proteìnas recombinantes
BRPI0516264-5A BRPI0516264A (pt) 2004-10-05 2005-10-05 molécula de ácido nucleico, seqüência de nucleotìdeos, cassete de expressão, vetor de expressão, célula, métodos para expressar um anticorpo recombinante ou fragmento do mesmo, para melhorar a expressão de um anticorpo recombinante ou fragmento do mesmo, para produzir um anticorpo recombinante ou fragmento do mesmo e uma preparação de anticorpos e para detectar um produto irt em uma amostra, anticorpo e composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0516264-5A BRPI0516264A (pt) 2004-10-05 2005-10-05 molécula de ácido nucleico, seqüência de nucleotìdeos, cassete de expressão, vetor de expressão, célula, métodos para expressar um anticorpo recombinante ou fragmento do mesmo, para melhorar a expressão de um anticorpo recombinante ou fragmento do mesmo, para produzir um anticorpo recombinante ou fragmento do mesmo e uma preparação de anticorpos e para detectar um produto irt em uma amostra, anticorpo e composição farmacêutica

Country Status (13)

Country Link
US (3) US7807804B2 (pt)
EP (2) EP1797182A2 (pt)
JP (2) JP2008515438A (pt)
KR (1) KR20070073885A (pt)
CN (2) CN101027391A (pt)
AU (2) AU2005294373B2 (pt)
BR (2) BRPI0516572A (pt)
CA (2) CA2582194A1 (pt)
EA (1) EA200700751A1 (pt)
IL (1) IL182182A0 (pt)
MX (2) MX2007003856A (pt)
WO (2) WO2006042158A2 (pt)
ZA (1) ZA200703561B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
UA87453C2 (ru) * 2003-02-01 2009-07-27 Вайет Применения фрагмента ав для лечения болезни альцгеймера
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2005214331B2 (en) * 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
EP1797182A2 (en) * 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
CA2583306A1 (en) * 2004-10-08 2006-08-10 Intronn, Inc. Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
WO2006066089A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
AU2007226696C1 (en) 2006-03-10 2016-02-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20130195881A1 (en) * 2007-04-27 2013-08-01 Sanjaya Singh Potent, stable and non-immunosuppressive anti-cd4 antibodies
US8314225B2 (en) * 2007-06-29 2012-11-20 Hoffman-La Roche Inc. Heavy chain mutant leading to improved immunoglobulin production
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2012005168A (es) * 2009-11-05 2012-06-08 Genentech Inc Metodos y composicion para secrecion de polipeptidos heterologos.
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
BR112014019861A2 (pt) 2012-02-17 2017-07-04 Seattle Genetics Inc anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
MX2016011637A (es) 2014-03-14 2017-04-13 Genentech Inc Metodos y composiciones para secrecion de polipeptidos heterologos.
DK3234128T3 (da) * 2014-12-16 2025-08-18 Garvan Institute Of Medical Res Sekventeringskontroller
WO2017005923A1 (en) * 2015-07-09 2017-01-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vector expressing membrane-anchored or secreted antibody
JP7511591B2 (ja) 2019-06-28 2024-07-05 エフ． ホフマン－ラ ロシュ アーゲー 抗体の製造方法
AU2020397070A1 (en) 2019-12-05 2022-07-14 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates
WO2022009047A1 (en) * 2020-07-08 2022-01-13 Astrazeneca Ab Methods of improving protein expression
EP4185612A4 (en) 2020-07-23 2024-12-25 Othair Prothena Limited Anti-abeta antibodies
EP4463476A1 (en) * 2022-01-13 2024-11-20 Astrazeneca AB Methods of improving protein expression
CN116844637B (zh) * 2023-07-07 2024-02-09 北京分子之心科技有限公司 一种获取第一源抗体序列对应的第二源蛋白质序列的方法与设备

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150141A (en) * 1993-09-10 2000-11-21 Trustees Of Boston University Intron-mediated recombinant techniques and reagents
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
CA2286305A1 (en) * 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) * 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
DE60229051D1 (de) * 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
CN100450551C (zh) * 2002-11-29 2009-01-14 中国医学科学院基础医学研究所 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途
UA87453C2 (ru) * 2003-02-01 2009-07-27 Вайет Применения фрагмента ав для лечения болезни альцгеймера
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1648675A2 (en) * 2003-05-30 2006-04-26 Koppers Industries of Delaware, Inc. Chopped carbon fiber preform processing method using coal tar pitch binder
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
MY144231A (en) * 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
KR101157694B1 (ko) * 2003-12-17 2012-06-20 와이어쓰 엘엘씨 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법
US7790956B2 (en) * 2004-04-02 2010-09-07 Cropdesign N.V. Plants having improved growth characteristics and methods for making the same by modulating expression of a nucleic acid sequence encoding a NAP1-like protein
EP1797182A2 (en) * 2004-10-05 2007-06-20 Wyeth a Corporation of the State of Delaware Methods and compositions for improving recombinant protein production
US20060160161A1 (en) * 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
WO2006066089A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
TW200636066A (en) * 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
TW200635608A (en) * 2004-12-15 2006-10-16 Neuralab Ltd Aβ antibodies for use in improving cognition
WO2006066118A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
US20060240486A1 (en) * 2004-12-15 2006-10-26 Johnson-Wood Kelly L Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2006207901A1 (en) * 2005-01-28 2006-08-03 Wyeth Stabilized liquid polypeptide formulations
CN101213211A (zh) * 2005-06-17 2008-07-02 惠氏公司 纯化含Fc区蛋白的方法
WO2008131298A2 (en) * 2007-04-18 2008-10-30 Elan Pharma International Limited Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe

Also Published As

Publication number Publication date
US7807804B2 (en) 2010-10-05
CN101027391A (zh) 2007-08-29
US20090285806A1 (en) 2009-11-19
AU2005294373A1 (en) 2006-04-20
US20110038863A1 (en) 2011-02-17
EP1828251A2 (en) 2007-09-05
AU2005294131A1 (en) 2006-04-20
EP1797182A2 (en) 2007-06-20
WO2006041934A3 (en) 2008-04-24
CN101287471A (zh) 2008-10-15
AU2005294373B2 (en) 2011-12-08
IL182182A0 (en) 2007-07-24
BRPI0516264A (pt) 2008-08-26
JP4980222B2 (ja) 2012-07-18
CA2582194A1 (en) 2006-04-20
WO2006042158A3 (en) 2006-06-22
MX2007003856A (es) 2007-09-19
EA200700751A1 (ru) 2008-06-30
EP1828251B1 (en) 2012-09-26
WO2006042158A2 (en) 2006-04-20
JP2008515438A (ja) 2008-05-15
MX2007003906A (es) 2007-05-21
ZA200703561B (en) 2009-09-30
JP2008515430A (ja) 2008-05-15
KR20070073885A (ko) 2007-07-10
EP1828251A4 (en) 2009-01-21
WO2006041934A2 (en) 2006-04-20
CA2582157A1 (en) 2006-04-20
CN101287471B (zh) 2012-10-03
US20060099206A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0516572A (pt) métodos e composições para melhorar a produção de proteìnas recombinantes
BRPI0612273C1 (pt) anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição
UA102503C2 (en) Interleukin-13 binding proteins
AR048025A1 (es) Plantas con actividad aumentada de una enzima fosforilante del almidon
SG170749A1 (en) Anti-ilt7 antibody
WO2004065417A3 (en) Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DE602006019050D1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
BR0306979A (pt) Polipeptìdeo isolado, proteìna de fusão, molécula isolada de polinucleotìdeo, vetor de expressão, célula cultivada, anticorpo ou fragmento de anticorpo, e, métodos para produzir uma proteìna, para produzir um anticorpo, para estimular uma resposta imune em um mamìfero, para expandir células hematopoiéticas e progenitores de células hematopoiéticas, para detectar a presença de rna zcytor17lig e de zcytor17lig em uma amostra biológica, para matar cérlulas cancerìgenas, para inibir a proliferação induzida por zcytor17lig ou diferenciação de células hematopoiéticas e progenitoras de células hematopoiéticas, para reduzir a inflamação induzida por zcytor17lig para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero acometido por uma doença inflamatória e para detectar inflamação em um paciente
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
MX2009002388A (es) Uso de celulas humanas originarias de leucemia mieloide para la expresion de anticuerpos.
MX2009002816A (es) Proteinas de fusion de albumina.
CY1108571T1 (el) Διεργασια για την παραγωγη και τον καθαρισμο ερυθροποιητινης
DE602008002593D1 (de) Verfahren zur herstellung eines rekombinanten polyklonalen proteins
EA200501774A1 (ru) Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
ATE521695T1 (de) Zirkuläres dna-molekül mit einem konditionalen replikationsursprung, verfahren zur herstellung davon und ihre verwendung in der gentherapie
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo
ATE515568T1 (de) Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide
UA92157C2 (ru) Способ продуцирования гормона роста
DK1904636T3 (da) Forbedringer inden for eller i sammenhæng med proteinfremstilling
BR0313083A (pt) moléculas de adamts4 modificadas,polinucleotìdeo, vetor, processos para produção, composição farmacêutica, bem como uso das mesmas
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2004013333A3 (de) Revertierung der negativ-selektiven wirkung von negativen markerproteinen als selektionsverfahren
ATE447013T1 (de) Polypeptide mit endoglucanase-aktivtät und dafür codierende polynukleotide
WO2010009227A3 (en) Recombinant pokeweed antiviral proteins, compositions and methods related thereto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.